Home » Stocks » NDRA

ENDRA Life Sciences Inc. (NDRA)

Stock Price: $1.74 USD 0.69 (65.71%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
After-hours: $1.81 +0.07 (4.02%) Jan 19, 4:54 PM
Market Cap 45.32M
Revenue (ttm) n/a
Net Income (ttm) -18.90M
Shares Out 23.89M
EPS (ttm) -0.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $1.74
Previous Close $1.05
Change ($) 0.69
Change (%) 65.71%
Day's Open 1.29
Day's Range 1.19 - 1.75
Day's Volume 17,390,802
52-Week Range 0.63 - 1.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Accesswire - 6 days ago

Now Has 78 Patents Issued, Filed, Licensed or in Preparation As Taeus® Commercial Launch Plans Advance ANN ARBOR, MI / ACCESSWIRE / January 13, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:...

Accesswire - 1 week ago

ANN ARBOR, MI / ACCESSWIRE / January 8, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that Chairman and CEO Franco...

Accesswire - 3 weeks ago

ANN ARBOR, MI / ACCESSWIRE / December 23, 2020 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has recently been issued Chinese Pat...

Accesswire - 4 weeks ago

Supports Commercialization of TAEUS Ⓡ Product for Imaging NAFLD/NASH to December 2023 ANN ARBOR, MI / ACCESSWIRE / December 21, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a pione...

Accesswire - 1 month ago

ANN ARBOR, MI / ACCESSWIRE / December 18, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a developer of enhanced ultrasound technologies, today reported the closing of its previously...

Seeking Alpha - 2 months ago

ENDRA Life Sciences Inc. (NDRA) CEO Francois Michelon on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 5 months ago

ENDRA Life Sciences Inc.'s (NDRA) CEO Francois Michelon on Q2 2020 Results - Earnings Call Transcript

Seeking Alpha - 6 months ago

TAEUS device fills the need for a non-invasive test for NASH.

Seeking Alpha - 8 months ago

ENDRA Life Sciences, Inc. (NDRA) CEO Francois Michelon on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 9 months ago

ENDRA Life Sciences, Inc. (NDRA) CEO Francois Michelon on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

ENDRA Life Sciences, Inc. (NDRA) CEO Francois Michelon on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

ENDRA Life Sciences' (NDRA) CEO Francois Michelon on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

ENDRA released data at the end of 2019Q1 that didn't live up to the market's expectation, sending its share price down to new lows.

Seeking Alpha - 1 year ago

ENDRA Life Sciences Inc. (NDRA) CEO Francois Michelon on Q1 2019 Results - Earnings Call Transcript

About NDRA

ENDRA Life Sciences develops technology for clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to gu... [Read more...]

Industry
Diagnostics & Research
IPO Date
May 9, 2017
CEO
Francois Michelon
Employees
15
Stock Exchange
NASDAQ
Ticker Symbol
NDRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for NDRA stock is "Strong Buy." The 12-month stock price forecast is 5.17, which is an increase of 197.13% from the latest price.

Price Target
$5.17
(197.13% upside)
Analyst Consensus: Strong Buy